Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic and endocrine related disorders. The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™ (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome. INGREZZA (valbenazine) capsules was approved by the FDA on April 11, 2017 for the treatment of adults with tardive dyskinesia and is currently commercialized by Neurocrine in the United States.

 

Bank Name Neurocrine Biosciences, Inc.
Stock Exchange NASDAQ
Symbol NBIX
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region Amarica
Chairman
CEO Dr. Kevin C. Gorman
Employees 440
Website www.neurocrine.com
Registered Year 1992

 

UpdateContent
UpdateContent
UpdateContent